Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Clinical Study on the Safety and Effectiveness of Pucotenlimab Combined With Standard Chemotherapy Regimen as Neoadjuvant Therapy for Children and Adolescents With Intermediate/High-Risk Rhabdomyosarcoma

NCT06456892 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT06456892
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06456892 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Clinical Study on the Safety and Effectiveness of Pucotenlimab Combined With Standard Chemotherapy Regimen as Neoadjuvant Therapy for Children and Adolescents With Intermediate/High-Risk Rhabdomyosarcoma
Lead sponsor
Sun Yat-sen University
Phase
Phase 1/2
Overall status
Recruiting
Start date
June 6, 2024
Completion date
December 6, 2026
Enrollment
82 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pediatric cancer, rhabdomyosarcoma